CN103070887B - 一种改性蛇毒凝胶剂及其制备方法 - Google Patents
一种改性蛇毒凝胶剂及其制备方法 Download PDFInfo
- Publication number
- CN103070887B CN103070887B CN201310036165.XA CN201310036165A CN103070887B CN 103070887 B CN103070887 B CN 103070887B CN 201310036165 A CN201310036165 A CN 201310036165A CN 103070887 B CN103070887 B CN 103070887B
- Authority
- CN
- China
- Prior art keywords
- snake venom
- modification
- gel
- deionized water
- venom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003998 snake venom Substances 0.000 title claims abstract description 92
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000003349 gelling agent Substances 0.000 title abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000008367 deionised water Substances 0.000 claims abstract description 18
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 18
- 239000011780 sodium chloride Substances 0.000 claims abstract description 17
- 239000000375 suspending agent Substances 0.000 claims abstract description 16
- 238000012986 modification Methods 0.000 claims description 58
- 230000004048 modification Effects 0.000 claims description 58
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 48
- 235000019441 ethanol Nutrition 0.000 claims description 29
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 17
- 229920002125 Sokalan® Polymers 0.000 claims description 17
- 229960001631 carbomer Drugs 0.000 claims description 17
- 229920000609 methyl cellulose Polymers 0.000 claims description 16
- 239000001923 methylcellulose Substances 0.000 claims description 16
- 235000010981 methylcellulose Nutrition 0.000 claims description 16
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 14
- 230000002421 anti-septic effect Effects 0.000 claims description 14
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 14
- 150000001298 alcohols Chemical class 0.000 claims description 13
- 229920000896 Ethulose Polymers 0.000 claims description 11
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 claims description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 11
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 claims description 11
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 11
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 11
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 11
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 8
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 8
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 8
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 8
- 241000416162 Astragalus gummifer Species 0.000 claims description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 7
- 229920001615 Tragacanth Polymers 0.000 claims description 7
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 7
- 239000004334 sorbic acid Substances 0.000 claims description 7
- 235000010199 sorbic acid Nutrition 0.000 claims description 7
- 229940075582 sorbic acid Drugs 0.000 claims description 7
- 239000000196 tragacanth Substances 0.000 claims description 7
- 235000010487 tragacanth Nutrition 0.000 claims description 7
- 229940116362 tragacanth Drugs 0.000 claims description 7
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 claims description 6
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 claims description 6
- 229960002900 methylcellulose Drugs 0.000 claims description 6
- 241000272144 Naja atra Species 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000002642 cobra venom Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 206010070834 Sensitisation Diseases 0.000 abstract description 17
- 230000008313 sensitization Effects 0.000 abstract description 17
- 230000000202 analgesic effect Effects 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 230000002335 preservative effect Effects 0.000 abstract 2
- 239000000499 gel Substances 0.000 description 46
- 238000012360 testing method Methods 0.000 description 16
- 238000003756 stirring Methods 0.000 description 14
- 229960004756 ethanol Drugs 0.000 description 13
- 229960004063 propylene glycol Drugs 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 230000036783 anaphylactic response Effects 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 238000001879 gelation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108010027612 Batroxobin Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000008252 pharmaceutical gel Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002303 anti-venom Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229910052728 basic metal Inorganic materials 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002242 deionisation method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
致敏发生率% | 皮肤致敏性评价 |
0-8 | 无致敏性 |
9-28 | 轻度致敏性 |
29-64 | 中度致敏性 |
65-80 | 重度致敏性 |
81-100 | 极强致敏性 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310036165.XA CN103070887B (zh) | 2013-01-30 | 2013-01-30 | 一种改性蛇毒凝胶剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310036165.XA CN103070887B (zh) | 2013-01-30 | 2013-01-30 | 一种改性蛇毒凝胶剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103070887A CN103070887A (zh) | 2013-05-01 |
CN103070887B true CN103070887B (zh) | 2014-09-03 |
Family
ID=48147733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310036165.XA Active CN103070887B (zh) | 2013-01-30 | 2013-01-30 | 一种改性蛇毒凝胶剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103070887B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102133232B (zh) * | 2011-03-18 | 2013-03-06 | 苏州大学 | 眼镜蛇毒物理改性方法和在制备镇痛或免疫抑制药物中的应用 |
CN102406665A (zh) * | 2011-11-16 | 2012-04-11 | 苏州人本药业有限公司 | 物理改性后的眼镜蛇蛇毒在制备治疗关节炎药物中的应用 |
CN102846666B (zh) * | 2012-07-04 | 2015-11-18 | 苏州人本药业有限公司 | 物理改性后的中华眼镜蛇蛇毒在制备治疗急、慢性肾病的药物中的用途 |
-
2013
- 2013-01-30 CN CN201310036165.XA patent/CN103070887B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN103070887A (zh) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104257639B (zh) | 一种用于创面治疗的涂膜剂及其制备方法 | |
CN103463124A (zh) | 一种细菌纤维素壳聚糖复合凝胶及其制备与体表创面愈合的应用 | |
MX2010002448A (es) | Formulacion liquida del g-csf conjugado. | |
CN107582691B (zh) | 复方黄柏液涂剂漱口凝胶 | |
TW201306845A (zh) | 包括植物為主的多醣之醫藥組合物及其用途 | |
CN103070887B (zh) | 一种改性蛇毒凝胶剂及其制备方法 | |
CN104740141A (zh) | 一种抗菌喷剂及其制备方法 | |
SG173581A1 (en) | Process for purifying guar | |
CN112716956B (zh) | 治疗感冒的日用型复方制剂及其制备方法 | |
CN114949089A (zh) | 一种除螨抑菌药品配方及其制备工艺 | |
CN113509493B (zh) | 一种促创面愈合的抑菌软膏及其制备方法 | |
CN106389359A (zh) | 供注射用的贝利司他药物组合物及其制备方法 | |
WO2022133628A1 (zh) | 一种可降解液体创可贴及其制备方法 | |
CN109078005B (zh) | 一种白消安组合物及其制备方法和应用 | |
CN103768011A (zh) | 福多司坦注射剂及其制备方法 | |
CN102266298A (zh) | 一种培美曲塞二钠的药物组合物 | |
JP2005247804A (ja) | 点眼剤 | |
CN103919779B (zh) | 一种含有莫西沙星的药物组合物 | |
CN102697703A (zh) | 一种吡罗昔康凝胶制剂及其制备方法 | |
CN103877578B (zh) | 一种注射用盐酸纳洛酮药物组合物及其制备方法 | |
CN105395490B (zh) | 一种含右旋雷贝拉唑钠药物组合物冻干粉针及其制备方法 | |
CN114832058B (zh) | 一种复方苦参凝胶及其制备方法和应用 | |
CN104557585A (zh) | 盐酸丁卡因晶体、含有盐酸丁卡因的组合物、及制备方法 | |
RU2010151994A (ru) | Фармацевтические композиции, включающие карбоксивинильный полимер и повидоновый полимер | |
CN102000049A (zh) | 含依替卡因异构体的注射用制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BAIDERUI (NANJING) BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SUZHOU RENBEN PHARMACEUTICAL CO., LTD. Effective date: 20141212 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215000 SUZHOU, JIANGSU PROVINCE TO: 211300 NANJING, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141212 Address after: Center branch No. 3 ancient Tan Road Gaochun Economic Development Zone Nanjing city Jiangsu province 211300 room 616 Patentee after: One hundred Reed (Nanjing) Biological Technology Co., Ltd. Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215000 BioBAY No. 218 building C20 Room 201 Patentee before: Suzhou Renben Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180118 Address after: 215123 room B07, room B07, National University Science Park, Soochow University, Suzhou, Suzhou, Jiangsu Patentee after: Suzhou Renben Pharmaceutical Co., Ltd. Address before: Center branch No. 3 ancient Tan Road Gaochun Economic Development Zone Nanjing city Jiangsu province 211300 room 616 Patentee before: One hundred Reed (Nanjing) Biological Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181101 Address after: 201403, 13 lane, Lane 850, LAN Feng Road, Fengxian District, Shanghai. Patentee after: Special bio medicine technology (Shanghai) Co., Ltd. Address before: 215123 Suzhou Industrial Park, Suzhou, Jiangsu. Room 307, building B07, National Science and Technology Park, Soochow University. Patentee before: Suzhou Renben Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181214 Address after: 215123 No. 328 Xing Hu Street, Suzhou Industrial Park, Jiangsu Patentee after: Suzhou Renben Pharmaceutical Co., Ltd. Address before: 201403, 13 lane, Lane 850, LAN Feng Road, Fengxian District, Shanghai. Patentee before: Special bio medicine technology (Shanghai) Co., Ltd. |